| 63 | 4 | 39 |
| 下载次数 | 被引频次 | 阅读次数 |
目的:对比依帕司他和羟苯磺酸钙联合全视网膜激光光凝(PRP)治疗重度非增生性糖尿病性视网膜病变(NPDR)的临床疗效。方法:选择100例重度NPDR患者,并随机分为依帕司他组和羟苯磺酸钙组,依帕司他组52例(71眼),羟苯磺酸钙组48例(69眼)。患者在进行全视网膜激光光凝(PRP)治疗后分别给予依帕司他和羟苯磺酸钙进行治疗。连续治疗3个月后评估各组患者的视力和眼底变化情况。结果:与羟苯磺酸钙组相比,依帕司他组患者视力和视野改善的有效率均明显增加,差异均有统计学意义(均P<0.05)。结论:依帕司他联合PRP治疗重度NPDR的疗效优于羟苯磺酸钙联合PRP。
Abstract：Objective:To compare the effects of epalrestat and calcium dobesilate on the severe nonproliferative diabetic retinopathy(NPDR)patients after pan-retinal laser photocoagulation(PRP).Methods:A total of 100 cases with severe NPDR were randomly divided into two groups.There were 52 cases with 71 eyes treated with epalrestat and PRP,and 48 cases with 69 eyes treated with calcium dobesilate and PRP.The changes of visual acuity and fundus were observed after 3months.Results:The effective rate in improvement of visual acuity and fundus were both higher in epalrestat group than that of calcium dobesilate group,both with significant difference(both P<0.05).Conclusion:Epalrestat combined with PRP is superior to calcium dobesilate combined with PRP in the treatment of severe NPDR.
[1]Fong D S,Aiello L,Gardner T W,et al.Retinopathy in diabetes[J].Diabetes Care,2004,Suppl 1:S84.
[2]Diabetic Retinopathy Study Research Group.Photocoagulation treatment of proliferative diabetic retinopathy:clinical applications of Diabetic Retinopathy Study(DRS)findings:DRS report number 8[J].Ophthalmology1981,88(7):583-600.
[3]Fong D S,Ferris F L 3rd,Davis M D,et al.Causes of severe visual loss in the early treatment diabetic retinopathy study:ETDRS report number 24.Early Treatment Diabetic Retinopathy Study Research Group[J].Am JOphthalmol,1999,127(2):137-141.
[4]张承芬.眼底病学[M].北京:人民卫生出版社,2010:289.
[5]Ip M S,Bressler S B,Antoszyk A N,et al.A randomized trial cornparing intravitreal triamcinolone and focal/grid photocoagulation for diabetic macular edema:baseline features[J].Retina,2008,28(7):919-930.
[6]Sivaprasad S,Prevost A T,Vasconcelos J C,et al.Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52weeks(CLARITY):a multicentre,single-blinded,randomised,controlled,phase 2b,non-inferiority trial[J].Lancet,2017,389(10085):2193-2203.
[7]Romero-Aroca P,Reyes-Torres J,Baget-Bernaldiz M,et al.Laser treatment for diabetic macular edema in the21st century[J].Curr Diabetes Rev,2014,10(2):100-112.
[8]齐佳,郭蕊,周云,等.应用多焦视网膜电图进行激光治疗糖尿病视网膜病的临床研究[J].临床眼科杂志,2017,25(2):125-128.
[9]Mukhtar A,Khan M S,Junejo M,et al.Effect of pan retinal photocoagulation on central macular thickness and visual acuity in proliferative diabetic retinopathy[J].Pak J Med Sci,2016,32(1):221-224.
[10]张欣,于强,于敏忠,等.光凝所致糖尿病视网膜病变视网膜功能改变的定量研究[J].中华眼底病杂志,2001,17(3):181-183.
[11]中华医学会眼科学会眼底病学组.我国糖尿病视网膜病变临床诊疗指南(2014年)[J].中华眼科杂志,2014,50(11):851-865.
[12]Cheung A K,Fung M K,Lo A C,et al.Aldose reductase deficiency prevents diabetes-induced blood-retinal barrierbreakdown,apoptosis,and glial reactivation in the retina of db/db mice[J].Diabetes,2005,54(11):3119-3125.
[13]张茉莉,田蓓,魏文斌.577、532nm激光全视网膜激光光凝治疗非增生型糖尿病视网膜病变疗效比较[J].中华眼底病杂志,2016,32(2):135-139.
[14]Chen C F,Liou S W,Wu H H,et al.Regulatory SNPs alter the gene expression of diabetic retinopathy associated secretary factors[J].Int J Med Sci,2016,13(9):717-723.
[15]崔颖,郭海科,韩云飞.2型糖尿病住院患者糖尿病视网膜病变患病率及危险因素分析[J].眼科新进展,2012,32(8):43-46.
[16]祖薇,辛志坤.口服药物对增生性糖尿病视网膜病变术后康复效果的影响[J].国际眼科杂志,2014,14(8):1516-1518.
基本信息:
中图分类号:R587.2;R779.63
引用信息:
[1]杜清,梁亮,张海江.依帕司他和羟苯磺酸钙联合全视网膜激光光凝治疗重度非增生性糖尿病性视网膜病变的临床研究[J].巴楚医学,2018,1(04):12-14+41.
基金信息:
国家自然科学基金面上项目(No:81770920)
2018-12-30
2018-12-30